COHORT STUDY:

N/A

OTHER REFERENCE(S):

1: Exposure to gemfibrozil and atorvastatin affects cholesterol metabolism and steroid production in zebrafish (Danio rerio).

[Al-Habsi Aziz A,Massarsky Andrey,Moon Thomas W]
Comp Biochem Physiol B Biochem Mol Biol.2016 Sep;199:87-96. doi: 10.1016/j.cbpb.2015.11.009. Epub 2015 Nov 25. PMID: 26627126

2: [The combinations of statins and fibrates: pharmacokinetic and clinical implications].

[González Santos Pedro]
Clin Investig Arterioscler.2014 Jul;26 Suppl 1:7-11. doi: 10.1016/S0214-9168(14)70019-1. PMID: 25043540

3: [Rhabdomyolysis secondary to simvastatin and phenofibrate].

[Forcadell-Peris M J,de Diego-Cabanes C]
Semergen.2014 May-Jun;40(4):e91-4. doi: 10.1016/j.semerg.2014.01.007. Epub 2014 Apr 24. PMID: 24768027

4: Lipid-lowering agents for nephrotic syndrome.

[Kong Xiangyu,Yuan Hao,Fan Junming,Li Zi,Wu Taixiang,Jiang Lanhui]
Cochrane Database Syst Rev.2013 Dec 10;(12):CD005425. doi: 10.1002/14651858.CD005425.pub2. PMID: 24327265

5: Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.

[Cziraky Mark J,Willey Vincent J,McKenney James M,Kamat Siddhesh A,Fisher Maxine D,Guyton John R,Jacobson Terry A,Davidson Michael H]
J Clin Lipidol.2013 Mar-Apr;7(2):102-8. doi: 10.1016/j.jacl.2012.06.006. Epub 2012 Jul 3. PMID: 23415428

6: Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters.

[Athyros Vasilios G,Mikhailidis Dimitri P]
Open Cardiovasc Med J.2012;6:122-5. doi: 10.2174/1874192401206010122. Epub 2012 Sep 20. PMID: 23066433

7: Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.

[Amend Kandace L,Landon Joan,Thyagarajan Veena,Niemcryk Steve,McAfee Andrew]
Ann Pharmacother.2011 Oct;45(10):1230-9. doi: 10.1345/aph.1Q110. Epub 2011 Sep 13. PMID: 21917557

8: Managing the underestimated risk of statin-associated myopathy.

[Rallidis Loukianos S,Fountoulaki Katerina,Anastasiou-Nana Maria]
Int J Cardiol.2012 Sep 6;159(3):169-76. doi: 10.1016/j.ijcard.2011.07.048. Epub 2011 Aug 2. PMID: 21813193

9: Reversal of drug-induced rhabdomyolysis on bone scan.

[Abrams Joseph,Tiu Serafin]
Clin Nucl Med.2011 Aug;36(8):e101-2. doi: 10.1097/RLU.0b013e31821c9ac1. PMID: 21716004

10: Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.

[Kar Subrata,Chockalingam Anand]
Am J Ther.2013 Jan;20(1):57-60. doi: 10.1097/MJT.0b013e3181ff7c79. PMID: 21192242

11: Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals.

[Metterlein T,Schuster F,Tadda L,Hager M,Roewer N,Anetseder M]
Cardiovasc Ther.2010 Dec;28(6):356-60. doi: 10.1111/j.1755-5922.2010.00237.x. Epub 2010 Oct 19. PMID: 20955541

12: Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.

[Kaspera Rüdiger,Naraharisetti Suresh B,Tamraz Bani,Sahele Tariku,Cheesman Matthew J,Kwok Pui-Yan,Marciante Kristin,Heckbert Susan R,Psaty Bruce M,Totah Rheem A]
Pharmacogenet Genomics.2010 Oct;20(10):619-29. doi: 10.1097/FPC.0b013e32833ecace. PMID: 20739906

13: Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.

[Karimi Sahar,Hough Augustus,Beckey Cherylyn,Parra David]
J Manag Care Pharm.2010 Sep;16(7):472-81. PMID: 20726676

14: Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.

[Kostapanos Michael S,Milionis Haralampos J,Elisaf Moses S]
Am J Cardiovasc Drugs.2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. PMID: 20104931

15: Gemfibrozil-induced myositis in a patient with normal renal function.

[Hahn Martin,Sriharan Kalavally,McFarland M Shawn]
Ann Pharmacother.2010 Jan;44(1):211-4. doi: 10.1345/aph.1M411. Epub 2009 Nov 24. PMID: 19934390

16: Plasmapheresis in a patient with rhabdomyolysis: a case report.

[Swaroop Rohina,Zabaneh Raja,Parimoo Nakul]
Cases J.2009 Aug 12;2:8138. doi: 10.4076/1757-1626-2-8138. PMID: 19918458

17: Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

[Wu Jianyong,Song Yan,Li Heng,Chen Jianghua]
Eur J Clin Pharmacol.2009 Dec;65(12):1169-74. doi: 10.1007/s00228-009-0723-7. Epub 2009 Sep 16. PMID: 19756555

18: Recovery time in a case of gemfibrozil and simvastatin-associated rhabdomyolysis.

[Cummins Dosha,Mackey Michael,Baker Erica]
South Med J.2009 Aug;102(8):858-60. doi: 10.1097/SMJ.0b013e3181ad6078. PMID: 19593291

19: Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.

[Silverberg Michael J,Leyden Wendy,Hurley Leo,Go Alan S,Quesenberry Charles P,Klein Daniel,Horberg Michael A]
Ann Intern Med.2009 Mar 3;150(5):301-13. PMID: 19258558

20: [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].

[Huić Mirjana,Anić Branimir,Cikes Nada,Bosnić Dubravka,Sentić Mirna,Markeljević Jasenka,Mayer Miroslav,Pazanin Leo]
Lijec Vjesn.2002 Mar-Apr;124(3-4):73-6. PMID: 18956824

21: Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

[Brinton Eliot A]
Curr Atheroscler Rep.2008 Feb;10(1):25-32. PMID: 18366982

22: Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

[Fazio Sergio]
Clin Ther.2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004. PMID: 18343268

23: Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.

[Martin Jill E,Cavanaugh Teresa M,Trumbull Leslie,Bass Maryetta,Weber Fredrick,Aranda-Michel Jaime,Hanaway Michael,Rudich Steven]
Clin Transplant.2008 Jan-Feb;22(1):113-9. doi: 10.1111/j.1399-0012.2007.00780.x. PMID: 18217912

24: Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.

[Holoshitz Noa,Alsheikh-Ali Alawi A,Karas Richard H]
Am J Cardiol.2008 Jan 1;101(1):95-7. Epub 2007 Nov 26. PMID: 18157972

25: Therapeutic rationale of combining therapy with gemfibrozil and simvastatin.

[Curtin Patrick O,Jones William N]
J Am Pharm Assoc (2003).2007 Mar-Apr;47(2):140-6. PMID: 17510000

26: Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population.

[Song Jessica C,Wang Clifford C,Huang Yi-Chao,Sanchez Jeannette,Nguyen Theresa,Khan Shamima,Kim Myo-Kyoung,Li Phoebe]
Am J Health Syst Pharm.2007 Apr 1;64(7):767-72. PMID: 17384364

27: Safety considerations with fibrate therapy.

[Davidson Michael H,Armani Annemarie,McKenney James M,Jacobson Terry A]
Am J Cardiol.2007 Mar 19;99(6A):3C-18C. Epub 2006 Dec 8. PMID: 17368275

28: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.

[Shepherd James,Vidt Donald G,Miller Elinor,Harris Susan,Blasetto James]
Cardiology.2007;107(4):433-43. Epub 2007 Mar 16. PMID: 17363845

29: [Gemfibrozil induced rhabdomyolysis in a patient with undiscovered hypothyroidism].

[Barquero-Romero J,Rodríguez Vázquez C,Arrobas Vacas I]
An Med Interna.2006 Oct;23(10):504-5. PMID: 17205640

30: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

[Neuvonen Pertti J,Niemi Mikko,Backman Janne T]
Clin Pharmacol Ther.2006 Dec;80(6):565-81. PMID: 17178259

31: Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure.

[Akoglu Hadim,Yilmaz Rahmi,Kirkpantur Alper,Arici Mustafa,Altun Bulent,Turgan Cetin]
Ann Pharmacother.2007 Jan;41(1):143-7. Epub 2006 Dec 5. PMID: 17148651

32: Risk factors for statin-associated rhabdomyolysis.

[Schech Stephanie,Graham David,Staffa Judy,Andrade Susan E,La Grenade Lois,Burgess Margaret,Blough David,Stergachis Andy,Chan K Arnold,Platt Richard,Shatin Deborah]
Pharmacoepidemiol Drug Saf.2007 Mar;16(3):352-8. PMID: 16892458

33: [A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins].

[Veyrac Gwenaëlle,Cellerin Laurent,Jolliet Pascale]
Therapie.2006 Jan-Feb;61(1):57-67. PMID: 16792155

34: Statin safety: a systematic review.

[Law Malcolm,Rudnicka Alicja R]
Am J Cardiol.2006 Apr 17;97(8A):52C-60C. Epub 2006 Feb 3. PMID: 16581329

35: Statin safety and drug interactions: clinical implications.

[Bottorff Michael B]
Am J Cardiol.2006 Apr 17;97(8A):27C-31C. Epub 2006 Jan 25. PMID: 16581325

36: [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].

[Saito Mitsuo,Hirata-Koizumi Mutsuko,Miyake Shinji,Hasegawa Ryuichi]
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku.2005;(123):41-5. PMID: 16541751

37: Fibrates in combination with statins in the management of dyslipidemia.

[Jacobson Terry A,Zimmerman Franklin H]
J Clin Hypertens (Greenwich).2006 Jan;8(1):35-41; quiz 42-3. PMID: 16407687

38: [Drug combinations: statins and fibrates].

[Xavier Hermes Toros]
Arq Bras Cardiol.2005 Oct;85 Suppl 5:34-5. Epub 2006 Jan 2. PMID: 16400396

39: Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats.

[Farswan Mamta,Rathod S P,Upaganlawar A B,Semwal Arvind]
Indian J Exp Biol.2005 Oct;43(10):845-8. PMID: 16235714

40: [Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin].

[Andréjak Michel,Gras Valérie,Caron Jacques]
Therapie.2005 May-Jun;60(3):299-304. PMID: 16128274

41: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.

[Wilke Russell A,Moore Jason H,Burmester James K]
Pharmacogenet Genomics.2005 Jun;15(6):415-21. PMID: 15900215

42: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

[Jones Peter H,Davidson Michael H]
Am J Cardiol.2005 Jan 1;95(1):120-2. PMID: 15619408

43: Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".

[Piorkowski Joseph D]
JAMA.2004 Dec 1;292(21):2655-7; discussion 2658-9. Epub 2004 Nov 22. PMID: 15572725

44: Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.

[Strom Brian L]
JAMA.2004 Dec 1;292(21):2643-6. Epub 2004 Nov 22. PMID: 15572722

45: Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

[Psaty Bruce M,Furberg Curt D,Ray Wayne A,Weiss Noel S]
JAMA.2004 Dec 1;292(21):2622-31. Epub 2004 Nov 22. PMID: 15572720

46: Simvastatin: a review.

[Pedersen Terje R,Tobert Jonathan A]
Expert Opin Pharmacother.2004 Dec;5(12):2583-96. PMID: 15571475

47: Risk of adverse events with fibrates.

[Alsheikh-Ali Alawi A,Kuvin Jeffrey T,Karas Richard H]
Am J Cardiol.2004 Oct 1;94(7):935-8. PMID: 15464682

48: Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.

[Chang Jennie T,Staffa Judy A,Parks Mary,Green Lanh]
Pharmacoepidemiol Drug Saf.2004 Jul;13(7):417-26. PMID: 15269925

49: Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

[Jamal Shelina M,Eisenberg Mark J,Christopoulos Stavroula]
Am Heart J.2004 Jun;147(6):956-65. PMID: 15199341

50: Safety of statins: focus on clinical pharmacokinetics and drug interactions.

[Bellosta Stefano,Paoletti Rodolfo,Corsini Alberto]
Circulation.2004 Jun 15;109(23 Suppl 1):III50-7. PMID: 15198967

51: Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy.

[Layne Richard D,Sehbai Aasim S,Stark Linda J]
Ann Pharmacother.2004 Feb;38(2):232-4. Epub 2003 Dec 15. PMID: 14742756

52: Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil.

[Morera Tomás,Gervasini Guillermo,Carrillo Juan A,Benitez Julio]
Eur J Clin Pharmacol.2004 Feb;59(12):917-21. Epub 2004 Jan 21. PMID: 14735257

53: Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.

[Farnier Michel]
Am J Cardiovasc Drugs.2003;3(3):169-78. PMID: 14727929

54: Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.

[Ehrhardt Manuela,Lindenmaier Heike,Burhenne Juergen,Haefeli Walter Emil,Weiss Johanna]
Biochem Pharmacol.2004 Jan 15;67(2):285-92. PMID: 14698041

55: Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature.

[Shammas Nicholas W,Kapalis Matthew J,Deckert Judi,Harris Melodee,Dippel Eric J,Labroo Ajay,McKinney Dawn]
Prev Cardiol.2003 Fall;6(4):189-94. PMID: 14605512

56: Pharmacological comparison of the statins.

[Klotz Ulrich]
Arzneimittelforschung.2003;53(9):605-11. PMID: 14558433

57: Clinical pharmacokinetics of atorvastatin.

[Lennernäs Hans]
Clin Pharmacokinet.2003;42(13):1141-60. PMID: 14531725

58: [Drug interactions with antilipemics].

[Becquemont Laurent]
Therapie.2003 Jan-Feb;58(1):85-90. PMID: 12822205

59: Statin-fibrate combination: therapy for hyperlipidemia: a review.

[Wierzbicki A S,Mikhailidis D P,Wray R,Schacter M,Cramb R,Simpson W G,Byrne C B]
Curr Med Res Opin.2003;19(3):155-68. PMID: 12814127

60: [Antilipemic therapy and rhabdomyolysis].

[Paragh György,Balogh Zoltán,Romics László]
Orv Hetil.2003 Mar 16;144(11):515-20. PMID: 12731338

61: Statin-associated myopathy.

[Thompson Paul D,Clarkson Priscilla,Karas Richard H]
JAMA.2003 Apr 2;289(13):1681-90. PMID: 12672737

62: Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.

[Maiguma Takayoshi,Fujisaki Koji,Itoh Yoshinori,Makino Kazutaka,Teshima Daisuke,Takahashi-Yanaga Fumi,Sasaguri Toshiyuki,Oishi Ryozo]
Naunyn Schmiedebergs Arch Pharmacol.2003 Mar;367(3):289-96. Epub 2003 Feb 8. PMID: 12644902

63: Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy.

[Yen Tzung-Hai,Chang Chiz-Tzung,Wu Mai-Szu,Huang Chiu-Ching]
Ren Fail.2003 Jan;25(1):139-43. PMID: 12617342

64: Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil.

[Arenas J,Fernández-Moreno M A,Molina J A,Fernández V,del Hoyo P,Campos Y,Calvo P,Martín M A,García A,Moreno T,Martínez-Salio A,Börnstein B,Bermejo F,Cabello A,Garesse R]
Neurology.2003 Jan 14;60(1):124-6. PMID: 12525734

65: Gemfibrozil greatly increases plasma concentrations of cerivastatin.

[Backman Janne T,Kyrklund Carl,Neuvonen Mikko,Neuvonen Pertti J]
Clin Pharmacol Ther.2002 Dec;72(6):685-91. PMID: 12496749

66: Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.

[Kind Amy Haavisto,Zakowski Laura J,McBride Patrick E]
WMJ.2002;101(7):53-6. PMID: 12426921

67: Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

[Talpur Rakhshandra,Ward Staci,Apisarnthanarax Narin,Breuer-Mcham Joan,Duvic Madeleine]
J Am Acad Dermatol.2002 Nov;47(5):672-84. PMID: 12399758

68: Rhabdomyolysis associated with gemfibrozil-colchicine therapy.

[Atmaca Hulusi,Sayarlioglu Hayriye,Külah Eyüp,Demircan Nejat,Akpolat Tekin]
Ann Pharmacother.2002 Nov;36(11):1719-21. PMID: 12398566

69: HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.

[Huynh T,Cordato D,Yang F,Choy T,Johnstone K,Bagnall F,Hitchens N,Dunn R]
Intern Med J.2002 Sep-Oct;32(9-10):486-90. PMID: 12380704

70: Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.

[McLaughlin Tracey,Abbasi Fahim,Lamendola Cindy,Leary Elizabeth,Reaven Gerald M]
Metabolism.2002 Oct;51(10):1355-9. PMID: 12370858

71: Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis.

[Su Mark,Hoffman Robert S,Flomenbaum Mark]
Am J Forensic Med Pathol.2002 Sep;23(3):305-6. PMID: 12198364

72: The myotoxicity of statins.

[Evans Marc,Rees Alan]
Curr Opin Lipidol.2002 Aug;13(4):415-20. PMID: 12151857

73: [Metabolic modifications related to immunosuppressive drugs].

[Ducobu J]
Rev Med Brux.2002 Jun;23(3):156-9. PMID: 12143154

74: Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

[Evans Marc,Rees Alan]
Drug Saf.2002;25(9):649-63. PMID: 12137559

75: [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence].

[SantaCruz P L,González A,León M E,Fernández M Y]
Nefrologia.2002;22(3):301-2. PMID: 12123135

76: Severe rhabdomyolysis related to cerivastatin without gemfibrozil.

[Hyman David J,Henry Andrea,Taylor Addison]
Ann Intern Med.2002 Jul 2;137(1):74. PMID: 12093260

77: Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine.

[Bairaktari Eleni,Seferiadis Konstantin,Liamis George,Psihogios Nikolaos,Tsolas Orestes,Elisaf Moses]
Clin Chem.2002 Jul;48(7):1106-9. PMID: 12089184

78: Lipid-lowering drugs: are adverse effects predictable and reversible?

[Muscari Antonio,Puddu Giovanni M,Puddu Paolo]
Cardiology.2002;97(3):115-21. PMID: 12077562

79: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

[Williams David,Feely John]
Clin Pharmacokinet.2002;41(5):343-70. PMID: 12036392

80: Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.

[Marsà Carretero Mireia,Alos Manrique Cristina,Valles Callol Joan-Antoni]
Br J Gen Pract.2002 Mar;52(476):235-6. PMID: 12030671

81: Statin stories.

Diabetes Obes Metab.2002 Mar;4(2):138. PMID: 11993442

82: Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.

[Maxa Jan L,Melton Larry B,Ogu Chris C,Sills Michael N,Limanni Alex]
Ann Pharmacother.2002 May;36(5):820-3. PMID: 11978159

83: Statin safety.

[Foxton J]
Nurs Stand.2001 Sep 19-25;16(1):20. PMID: 11977679

84: Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy.

[Roca Bernardino,Calvo Begoña,Monferrer Rafael]
Ann Pharmacother.2002 Apr;36(4):730-1. PMID: 11936088

85: Myopathy and rhabdomyolysis with lipid-lowering drugs.

[Hodel Christian]
Toxicol Lett.2002 Mar 10;128(1-3):159-68. PMID: 11869826

86: [Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil].

[Bosch Rovira T,Llompart Pou J A,Forteza-Rey J]
Rev Clin Esp.2001 Dec;201(12):731-2. PMID: 11835892

87: Withdrawal of cerivastatin from the world market.

[Furberg Curt D,Pitt Bertram]
Curr Control Trials Cardiovasc Med.2001;2(5):205-207. PMID: 11806796

88: [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].

[Sirvent A E,Cabezuelo J B,Enríquez R,Amorós F,González C,Reyes A]
Nefrologia.2001 Sep-Oct;21(5):497-500. PMID: 11795020

89: Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.

[Kamaliah M D,Sanjay L D]
Singapore Med J.2001 Aug;42(8):368-72. PMID: 11764054

90: Statin-associated myopathy.

[Hamilton-Craig I]
Med J Aust.2001 Nov 5;175(9):486-9. PMID: 11758079

91: Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil.

[Hendriks F,Kooman J P,van der Sande F M]
Nephrol Dial Transplant.2001 Dec;16(12):2418-9. PMID: 11733637

92: Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?

[Langford N J,Kendall M J]
J Clin Pharm Ther.2001 Dec;26(6):391-5. PMID: 11722675

93: Fatal rhabdomyolysis caused by lipid-lowering therapy.

[Federman D G,Hussain F,Walters A B]
South Med J.2001 Oct;94(10):1023-6. PMID: 11702815

94: [Cerivastatin and gemfibrozil: a dangerous combination].

[Tormo Molina J,Gázquez Pérez I,Matas Hoces A]
Aten Primaria.2001 Oct 15;28(6):438-9. PMID: 11602128

95: [Fatal rhabdomyolysis caused by cerivastatin].

[Scheen A J]
Rev Med Liege.2001 Aug;56(8):592-4. PMID: 11584446

96: Cerivastatin and gemfibrozil-associated rhabdomyolysis.

[Bruno-Joyce J,Dugas J M,MacCausland O E]
Ann Pharmacother.2001 Sep;35(9):1016-9. PMID: 11573847

97: Bayer pulls cerivastatin (Baycol) from market.

[Wooltorton E]
CMAJ.2001 Sep 4;165(5):632. PMID: 11563216

98: [Severe rhabdomyolysis associated with cerivastatin and gemfibrozil].

[de Arriba Méndez J J,Gómez Merino E,Sáez Barcelona J A,Sáez Méndez L]
Med Clin (Barc).2001 Sep 15;117(7):278-9. PMID: 11562335

99: Baycol withdrawn from market.

[SoRelle R]
Circulation.2001 Aug 21;104(8):E9015-6. PMID: 11521677

100: Bayer decides to withdraw cholesterol lowering drug.

[Charatan F]
BMJ.2001 Aug 18;323(7309):359. PMID: 11509419

101: Statin-fibrate combination therapy.

[Shek A,Ferrill M J]
Ann Pharmacother.2001 Jul-Aug;35(7-8):908-17. PMID: 11485144

102: Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.

[Lau T K,Leachman D R,Lufschanowski R]
Tex Heart Inst J.2001;28(2):142-5. PMID: 11453128

103: [Rhabdomyolysis complicated with acute renal insufficiency in a patient treated with gemfibrozil and cerivastatin].

[Vascónez Espinosa F,Gómez Rodríguez N,Martín Joven A,Posada García F J]
Rev Clin Esp.2001 Apr;201(4):228-9. PMID: 11447919

104: Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable?

[Tomlinson B,Lan I W]
Am J Med.2001 Jun 1;110(8):669-70. PMID: 11388340

105: Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia.

[Mastroianni C M,d'Ettorre G,Forcina G,Lichtner M,Corpolongo A,Coletta S,Vullo V]
AIDS.2001 Apr 13;15(6):820-1. PMID: 11371708

106: Pharmacotherapy of hypercholesterolaemia: statins in clinical practice.

[Moghadasian M H,Mancini G B,Frohlich J J]
Expert Opin Pharmacother.2000 May;1(4):683-95. PMID: 11249510

107: Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.

[Oldemeyer J B,Lund R J,Koch M,Meares A J,Dunlay R]
Cardiology.2000;94(2):127-8. PMID: 11173785

108: Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.

[Plosker G L,Dunn C I,Figgitt D P]
Drugs.2000 Nov;60(5):1179-206. PMID: 11129127

109: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil.

[Alexandridis G,Pappas G A,Elisaf M S]
Am J Med.2000 Aug 15;109(3):261-2. PMID: 11023440

110: A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.

[Ozdemir O,Boran M,Gökçe V,Uzun Y,Koçak B,Korkmaz S]
Angiology.2000 Aug;51(8):695-7. PMID: 10959522

111: Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure.

[Al Shohaib S]
Am J Nephrol.2000 May-Jun;20(3):212-3. PMID: 10878403

112: Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil.

[Bermingham R P,Whitsitt T B,Smart M L,Nowak D P,Scalley R D]
Am J Health Syst Pharm.2000 Mar 1;57(5):461-4. PMID: 10711527

113: Micronized fenofibrate: a new fibric acid hypolipidemic agent.

[Guay D R]
Ann Pharmacother.1999 Oct;33(10):1083-103. PMID: 10534222

114: Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

[Moghadasian M H]
Life Sci.1999;65(13):1329-37. PMID: 10503952

115: Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics.

[Landesman K A,Stozek M,Freeman N J]
Conn Med.1999 Aug;63(8):455-7. PMID: 10500341

116: Dual hepatic metabolism of cerivastatin--clarifications.

[Guyton J R,Dujovne C A,Illingworth D R]
Am J Cardiol.1999 Aug 15;84(4):497. PMID: 10468102

117: Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.

[Pogson G W,Kindred L H,Carper B G]
Am J Cardiol.1999 Apr 1;83(7):1146. PMID: 10190540

118: Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.

[Yee H S,Fong N T]
Ann Pharmacother.1998 Oct;32(10):1030-43. PMID: 9793596

119: Rhabdomyolysis after taking atorvastatin with gemfibrozil.

[Duell P B,Connor W E,Illingworth D R]
Am J Cardiol.1998 Feb 1;81(3):368-9. PMID: 9468088

120: Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.

[Athyros V G,Papageorgiou A A,Hatzikonstandinou H A,Didangelos T P,Carina M V,Kranitsas D F,Kontopoulos A G]
Am J Cardiol.1997 Sep 1;80(5):608-13. PMID: 9294990

121: Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

[Tal A,Rajeshawari M,Isley W]
South Med J.1997 May;90(5):546-7. PMID: 9160078

122: Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil.

[van Puijenbroek E P,Du Buf-Vereijken P W,Spooren P F,van Doormaal J J]
J Intern Med.1996 Dec;240(6):403-4. PMID: 9010388

123: Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy.

[Górriz J L,Sancho A,Lopez-Martin J M,Alcoy E,Catalán C,Pallardó L M]
Nephron.1996;74(2):437-8. PMID: 8893176

124: Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy.

[Abdul-Ghaffar N U,el-Sonbaty M R]
J Clin Gastroenterol.1995 Dec;21(4):340-1. PMID: 8583121

125: Currently available hypolipidaemic drugs and future therapeutic developments.

[Farmer J A,Gotto A M]
Baillieres Clin Endocrinol Metab.1995 Oct;9(4):825-47. PMID: 8593127

126: Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.

[Kirk J K,Dupuis R E]
Ann Pharmacother.1995 Sep;29(9):879-91. PMID: 8547738

127: Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

[Garnett W R]
Am J Health Syst Pharm.1995 Aug 1;52(15):1639-45. PMID: 7583826

128: Pharmacokinetics of the combination of fluvastatin and gemfibrozil.

[Spence J D,Munoz C E,Hendricks L,Latchinian L,Khouri H E]
Am J Cardiol.1995 Jul 13;76(2):80A-83A. PMID: 7604806

129: Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.

[Hutchesson A C,Moran A,Jones A F]
J Clin Pharm Ther.1994 Dec;19(6):387-9. PMID: 7876371

130: Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants.

[de Alava E,Sola J J,Lozano M D,Pardo-Mindán F J]
Nephron.1994;66(2):242-3. PMID: 8139752

131: Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil.

[Knoll R W,Ciafone R,Galen M]
Conn Med.1993 Sep;57(9):593-4. PMID: 8252847

132: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.

[Glueck C J,Oakes N,Speirs J,Tracy T,Lang J]
Am J Cardiol.1992 Jul 1;70(1):1-9. PMID: 1615846

133: Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations.

[Ballantyne C M,Radovancevic B,Farmer J A,Frazier O H,Chandler L,Payton-Ross C,Cocanougher B,Jones P H,Young J B,Gotto A M]
J Am Coll Cardiol.1992 May;19(6):1315-21. PMID: 1564233

134: Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs.

[Wallace C S,Mueller B A]
Ann Pharmacother.1992 Feb;26(2):190-2. PMID: 1554929

135: Gemfibrozil-induced myopathy.

[Magarian G J,Lucas L M,Colley C]
Arch Intern Med.1991 Sep;151(9):1873-4. PMID: 1888257

136: [Side effects of fibrates (except liver and muscle)].

[Sgro C,Escousse A]
Therapie.1991 Sep-Oct;46(5):351-4. PMID: 1754977

137: Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.

[Zimetbaum P,Frishman W H,Kahn S]
J Clin Pharmacol.1991 Jan;31(1):25-37. PMID: 2045526

138: Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects.

[Wanner C,Frommherz K,Hörl W H]
Cardiology.1991;78(3):202-17. PMID: 1868498

139: Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil.

JAMA.1990 Dec 19;264(23):2991-2. PMID: 2243420

140: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.

[Pierce L R,Wysowski D K,Gross T P]
JAMA.1990 Jul 4;264(1):71-5. PMID: 2355431

141: Lovastatin-induced acute rhabdomyolysis.

[Kogan A D,Orenstein S]
Postgrad Med J.1990 Apr;66(774):294-6. PMID: 2385552

142: Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.

[Marais G E,Larson K K]
Ann Intern Med.1990 Feb 1;112(3):228-30. PMID: 2297197

143: The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis.

[Goldman J A,Fishman A B,Lee J E,Johnson R J]
Arthritis Rheum.1989 Mar;32(3):358-9. PMID: 2930608